Proxima · 1 day ago
Analyst Intern Program
New York
Internship
Onsite
InternProxima is advancing a new approach to drug discovery by making protein interactions programmable. The Analyst Intern Program offers students the opportunity to work across different teams and functions, allowing them to own projects and make a meaningful impact on Proxima’s innovative science and technology.
Alternative MedicineArtificial Intelligence (AI)BiotechnologyClinical TrialsLife ScienceMachine Learning
No H1B
Responsibilities
Utilizing systems biology (e.g. analyzing gene/protein expression data and interactome data from NeoLink) and structural biology (e.g. structural compatibility analysis using Neo-1) approaches to prioritize targets; Integrate competitive intelligence by assessing investor sentiment, market opportunity and commercial viability against competitor pipelines; Target evaluation and due diligence of novel targets
Overlay our proprietary NeoLink data with public resources (BioGRID/IntAct/STRING, DepMap, OpenTargets, gnomAD constraint, GTEx) to find 'known vs new-to-science' and high-value gaps, designing an automated way to leverage LLMs to retrieve relevant information in the literature (e.g., protein-protein interactions experimentally verified by academic labs)
Identification and evaluation of strategic business partners across Pharma and Biotech landscape; Work to position the platform or program in a way that aligns with pharma portfolio gaps, therapeutic strategy, and risk tolerance; Work with BD and Scientific Project Leads to ensure we meet milestones, data packages are partnership-ready, and partner feedback loops back into program prioritization
For a prioritized target, work with the Proxima team to conduct end-to-end biological and/or chemistry due diligence and hypothesis generation to propose a new therapeutic strategy (e.g., induced-proximity mechanism such as glue/degrader/stabilizer), including target biology review, pathway/cell-context mapping, NeoLink-driven interaction hypotheses, evaluating chemical matter using in silico approaches, key risks/competition assessment, and a concrete experimental plan
Qualification
Required
Enrolled in a 4-year undergraduate program, 2-year masters program, PhD program
Currently pursuing a related field of study in life sciences or computer science/ML/AI (e.g., Biology, Chemistry, Biochemistry, Computer Science, Machine Learning, Mathematics etc) combined with a concentration or previous work experience in applied economics or business OR a degree in applied economics or business, combined with a concentration or previous work experience in the life sciences
Track record of academic excellence; GPA of 3.5 or higher
Willingness to relocate to New York, NY for duration of program (role contingent)
Authorization to work in the U.S. This role is not eligible for visa sponsorship
Preferred
Ambitious & Driven. Passionate for Proxima's mission to revolutionize drug discovery with generative AI, structural proteomics and proximity modulation
Curious & Analytical. Superior verbal and written communication skills; ability to translate complex concepts into clear, concise recommendations
Self-Directed. Independently capable of seeking information, solving conceptual problems, corralling resources, and delivering results in challenging situations. Hungry to get things done with minimal direction. Thriving in ambiguity
Conscientious & Detail Oriented. Strong multi-tasking, organizational, and project planning skills, and a demonstrated ability to meet aggressive deadlines, coupled with strong interpersonal skills
Impatient & Scrappy. Ability to get things done, while quickly adapting to a rapidly changing environment; demonstrated capacity for creative problem-solving, coupled with a can-do attitude to overcome any obstacle. Relentlessness. Persistent. Bias for action
Prior internship experience in techbio, biotech, tech or related field preferred but not required
Company
Proxima
Proxima Bio develops programmable medicines that modulate protein interactions to address disease processes.
Founded in 2019
11-50 employees
Funding
Current Stage
Early StageTotal Funding
$86.26MKey Investors
DCVC
2026-01-13Seed· $86.26M
Leadership Team
Zachary Carpenter
Founder & CEO
Luca Naef
Co-Founder & CTO
Recent News
2025-10-30
Company data provided by crunchbase